Phase 2 Seattle Dietary Biomarkers Development Center

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-18

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Seattle Dietary Biomarker Development Center (S-DBDC) aims to advance the science of measuring dietary intake by identification and validation of dietary biomarkers that improve upon self-reported diet. To accomplish this mission, the Seattle DBDC will carry out controlled feeding studies in healthy human volunteers. Metabolomics assays will be conducted on blood and urine specimens collected during the feeding studies for biomarker identification. Stool samples will be collected and archived.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 Seattle Dietary Biomarkers Development Center

NCT05580653

Healthy Adults

COMPLETED NA

Developing Biomarkers of Dietary Intake

NCT01237093

Diet Therapy Healthy Volunteers

COMPLETED PHASE1

Dietary Biomarkers Intervention Core

NCT05616585

Biological Markers Diet, Healthy Metabolomics +1 more

COMPLETED NA

Effect of Diets on the Gut Microbiota Composition and Cardiometabolic Wellbeing

NCT03539666

Healthy

COMPLETED NA

Fruit and Vegetable Biomarker Discovery

NCT05621863

Biomarkers

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The central mission of the Seattle Dietary Biomarker Development Center (DBDC) is to advance the science of measuring complex dietary exposures by rigorous identification and validation of dietary biomarkers that improve upon measurement error-prone self-reported diet. To accomplish this mission, the Seattle DBDC first conducted a Phase 1 study for biomarker discovery; the Phase 1 study is registered and reported in a separate clinicaltrials.gov record (NCT05580653) as the study design differs from Phase 2.

In Phase 2 (registered in this current clinicaltrials.gov record), the Seattle DBDC will conduct a two-period, crossover, controlled feeding trial to evaluate whether the food biomarkers discovered in Phase 1 are detectable within the context of higher and lower Healthy Eating Index (HEI) 2020 diet patterns and to discover metabolomic biomarkers of higher and lower HEI-2020 diet patterns. A total of 30 healthy adults will complete two feeding periods in random order. Each feeding period consists of a 2-day run-in of controlled feeding followed by a 7-day feeding period, with at least a 7-day washout between feeding periods. Metabolomics assays will be conducted on blood and urine specimens collected during the feeding studies for biomarker identification and validation. Stool samples will be collected and archived for future studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized cross-over

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Statisticians Laboratory personnel

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: Higher HEI-2020 diet followed by lower HEI-2020 diet

Group Type EXPERIMENTAL

Higher HEI-2020 diet followed by lower HEI-2020 diet

Intervention Type OTHER

Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.

Arm 2: Lower HEI-2020 diet followed by higher HEI-2020 diet

Group Type EXPERIMENTAL

Lower HEI-2020 diet followed by higher HEI-2020 diet

Intervention Type OTHER

Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Higher HEI-2020 diet followed by lower HEI-2020 diet

Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.

Intervention Type OTHER

Lower HEI-2020 diet followed by higher HEI-2020 diet

Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults;
* Age 18 years or older;
* Willing to come to the Fred Hutch campus 10 times during the study; BMI 18.5-39.9 kg/m2

Exclusion Criteria

* Pregnancy or lactation;
* allergy or aversion to any of the foods that will be studied and/or provided;
* history of gastrointestinal disorders including ulcerative colitis, Crohn's disease, celiac sprue, hereditary non-polyposis colorectal cancer (HNPCC), familial adenomatous polyposis, pancreatic disease, or liver disease;
* previous gastrointestinal resection or bariatric surgery;
* bleeding disorders that precludes blood draws;
* recent hospital admissions (past 6 months) for heart disease (MI/CVA or CHF) or other CVD/CAD conditions under physician guided therapy that is not medically stable;
* cancer under radiation or chemotherapy treatment that is active or within 6 months of treatment;
* weight change (±5% in the last 3 months);
* regular alcohol intake of \> 2 drinks/day (equivalent to 720 mL of beer, 240 mL of wine, or 90 mL of spirits), and unwilling to abstain during feeding periods;
* use of tobacco and/or marijuana, hookahs, e-cigarettes (e-cigs, vapes, etc) and not willing to abstain during feeding periods;
* use of illicit drugs and not willing to abstain during feeding periods;
* BMI ≥40 kg/m2; regular (daily to weekly) use of over-the-counter (OTC) weight-loss aids or anti-inflammatories, and unwilling or unable to stop taking these during feeding periods;
* unwilling to stop taking OTC dietary supplements that interfere with the test foods being studied including pills, chewables, liquids or powders for the following: protein supplements, soy, fiber, flaxseed, fish oil (including cod liver oil), probiotics, carotenoids, selenium, other antioxidants, other phytochemicals, glucosamine and chondroitin (if vitamin supplement is MD prescribed - may continue);
* oral or IV antibiotic use in the past 6 months (could defer participation until 6 months post-completion of course of antibiotics);
* seated blood pressure \>140/90 mmHg; fasting clinical lab tests outside acceptable values as ascertained at the screening blood draw (see Table 2 in protocol document);
* current use of specific prescription medication(s) (see Table 3 in protocol document); and
* inability to freely give informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes